BioCentury
ARTICLE | Top Story

Biovitrum terminating obesity compound

May 22, 2003 7:00 AM UTC

Biovitrum (Stockholm, Sweden) and GlaxoSmithKline (LSE:GSK; GSK) said they would shorten a Phase IIb trial in 350 patients of BVT.933 selective serotonin (5-HT2C) receptor agonist to treat obesity and...